256 Newsroom — Uganda's Digital News Infrastructure
Business

Amylyx Stock Surges 55% After GLP-1 Blocker Hits All Trial Goals - Barron's

Published by Barron's By Mackenzie Tatananni · 18 August 2026 at 21:11
Share
Amylyx Stock Surges 55% After GLP-1 Blocker Hits All Trial Goals - Barron's
Image · Barron's

What the report says

Amylyx Pharmaceuticals says its GLP-1 receptor antagonist, avexitide, met both the primary and secondary endpoints in a late-stage clinical trial.

Read the full report at Barron's →

Loading debate for this article…

Other publishers covering this story

No additional verified coverage is currently clustered with this report.

More stories by this journalist

Other publications from this journalist — open any story without leaving the article page.

No other published stories from this publisher yet.

Related reporting

256 Newsroom Tax red flags that will put businesses in trouble in 2026/27 - Daily MonitorDaily Monitor Roosevelt Africa Trail Links Uganda, U.S. East Africa in Push for Trade and InvestmentNile Post 256 Newsroom How rice farming is fuelling poverty in Bukedi Sub-region - Daily MonitorDaily Monitor 256 Newsroom The sweet treats fuelling cavities - Daily MonitorDaily Monitor Mutasingwa: BRICS offers Uganda new opportunities in trade, investment and technologyNile Post Smallholder farmers to get relief from Equity GroupThe Observer